[Clinical considerations on the use of non-digitalic cardiokinetic drugs and vasodilators in cardiac insufficiency].
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D002395:Catecholamines / Q000627:therapeutic use; D000242:Cyclic AMP / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D005996:Nitroglycerin / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D013566:Sympathomimetics / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D002395:Catecholamines; D013566:Sympathomimetics; D014665:Vasodilator Agents; D009599:Nitroprusside; D005934:Glucagon; D000242:Cyclic AMP; D005996:Nitroglycerin; D010646:Phentolamine
Considerazioni cliniche sull'uso dei cardiocinetici non digitalici e dei vasodilatatori nella insufficienza cardiaca